CNX Therapeutics to accelerate European growth strategy with Inflexion's £2.3bn Continuation Fund

CNX Therapeutics to accelerate European growth strategy with Inflexion's £2.3bn Continuation Fund

London, May 15^th, 2025 – CNX Therapeutics Limited (“CNX Therapeutics”), a European specialty pharmaceutical platform dedicated to the supply of essential medicines, has been selected as one of four high-performing portfolio companies for Inflexion's newly announced Continuation Fund, which closed at £2.3 billion – the largest multi-asset continuation fund raised in Europe to date.

This strategic move will provide CNX Therapeutics with enhanced opportunities to drive our ambitious growth plans throughout Europe, with a particular focus on M&A and in-licensing activities, while leveraging Inflexion's ongoing partnership and investment expertise.

Guy Clark, CEO of CNX Therapeutics, commented: "This is a significant milestone for CNX Therapeutics that validates our strategy and performance to date. Inflexion's continued investment and support through this new fund will enable us to accelerate our growth trajectory, pursue strategic acquisitions, and further strengthen our position as a leading provider of essential medicines across Europe. We're excited about the opportunities this creates for our business, our employees, and ultimately the healthcare professionals and patients we serve."

The Continuation Fund comprises a select portfolio of global leaders across sectors. CNX joins Aspen Pumps, Rosemont Pharmaceuticals and Ocorian in this exclusive group identified for their growth potential.

Flor Kassai, Managing Partner at Inflexion, commented, “Aspen, CNX, Rosemont, and Ocorian all have clear growth strategies and we are excited to continue to partner with them.  In particular, there is a significant opportunity to turbocharge their growth through M&A.”

George Collier, Chief Operating Officer at Inflexion, commented, “We’re incredibly grateful to our existing and new investors for their continued support, as well as the outstanding management teams at Aspen, CNX, Rosemont and Ocorian. We’re excited about the road ahead and look forward to continuing to deliver growth across these four companies in the years to come.

With a diverse portfolio of 20+ marketed products – including 14 injectables and 6 CNS products – CNX delivers essential medicines to patients in more than 50 markets globally. The company's commitment to sustainability, recently highlighted by its progress toward B Corp certification, further differentiates it within the mid-market pharmaceutical sector.

The transaction is subject to applicable regulatory approvals.